Jason Henry, MD
Assistant Director, Phase 1 Research, Sarah Cannon Research Institute at HealthONE
Dr. Henry serves as assistant director of phase 1 research for Sarah Cannon Research Institute at HealthONE. In his role, Dr. Henry conducts clinical trials with a focus on gastrointestinal (GI) malignancies at the Sarah Cannon drug development unit in Denver providing patients with access to cutting-edge therapies, including phase 1 studies.
Dr. Henry completed his fellowship in hematology-oncology at the MD Anderson Cancer Center and his internship and residency at the University of Colorado’s Department of Internal Medicine. He received his Doctorate of Medicine from the University of North Dakota School of Medicine.
In addition to receiving numerous ASCO merit awards, Dr. Henry received the ASCO Conquer Cancer Foundation Young Investigator Award for his role as a principal investigator in researching the validation of biomarkers of autophagic flux in patients with RAS mutant tumors in response to MAPKi in colorectal cancer.